

# Reuben M Tooze

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8577178/publications.pdf>

Version: 2024-02-01

71  
papers

4,457  
citations

147801

31  
h-index

118850

62  
g-index

80  
all docs

80  
docs citations

80  
times ranked

5529  
citing authors

#	ARTICLE	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	7.2	1,023
2	Blimp1 Defines a Progenitor Population that Governs Cellular Input to the Sebaceous Gland. <i>Cell</i> , 2006, 126, 597-609.	28.9	396
3	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. <i>Blood</i> , 2020, 135, 1759-1771.	1.4	271
4	Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 649-662.	10.7	187
5	Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 202-212.	1.6	187
6	CD19 as a Membrane-Anchored Adaptor Protein of B Lymphocytes: Costimulation of Lipid and Protein Kinases by Recruitment of Vav. <i>Immunity</i> , 1998, 8, 635-645.	14.3	177
7	Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation. <i>Nature Immunology</i> , 2001, 2, 542-547.	14.5	169
8	Reprogramming Primordial Germ Cells into Pluripotent Stem Cells. <i>PLoS ONE</i> , 2008, 3, e3531.	2.5	140
9	Counterregulation by the Coreceptors CD19 and CD22 of MAP Kinase Activation by Membrane Immunoglobulin. <i>Immunity</i> , 1997, 7, 59-67.	14.3	115
10	In Vitro Generation of Long-lived Human Plasma Cells. <i>Journal of Immunology</i> , 2012, 189, 5773-5785.	0.8	111
11	Blimp1 homolog Hobit identifies effector-type lymphocytes in humans. <i>European Journal of Immunology</i> , 2015, 45, 2945-2958.	2.9	94
12	Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. <i>British Journal of Haematology</i> , 2012, 159, 441-453.	2.5	81
13	Co-receptors of B lymphocytes. <i>Current Opinion in Immunology</i> , 1997, 9, 324-329.	5.5	75
14	A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. <i>Scientific Reports</i> , 2018, 8, 5793.	3.3	70
15	Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. <i>Oncogene</i> , 2003, 22, 7750-7761.	5.9	66
16	Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. <i>Leukemia</i> , 2020, 34, 1329-1341.	7.2	66
17	A Microarray Platform-Independent Classification Tool for Cell of Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell Lymphoma. <i>PLoS ONE</i> , 2013, 8, e55895.	2.5	64
18	Biallelic interferon regulatory factor 8 mutation: A complex immunodeficiency syndrome with dendritic cell deficiency, monocytopenia, and immune dysregulation. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2234-2248.	2.9	63

#	ARTICLE	IF	CITATIONS
19	TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. <i>Journal of Autoimmunity</i> , 2014, 50, 59-66.	6.5	59
20	Prdm1 Regulates Thymic Epithelial Function To Prevent Autoimmunity. <i>Journal of Immunology</i> , 2017, 199, 1250-1260.	0.8	53
21	An extended set of PRDM1/BLIMP1 target genes links binding motif type to dynamic repression. <i>Nucleic Acids Research</i> , 2010, 38, 5336-5350.	14.5	52
22	Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity. <i>Journal of Immunology</i> , 2016, 197, 1447-1459.	0.8	52
23	Development of T-leukaemias in CD45 tyrosine phosphatase-deficient mutant lck mice. <i>EMBO Journal</i> , 2000, 19, 4644-4654.	7.8	48
24	BLIMP-1 is a target of cellular stress and downstream of the unfolded protein response. <i>European Journal of Immunology</i> , 2006, 36, 1572-1582.	2.9	48
25	BLIMP-1 and STAT3 Counterregulate MicroRNA-21 during Plasma Cell Differentiation. <i>Journal of Immunology</i> , 2012, 189, 253-260.	0.8	44
26	SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity. <i>Nucleic Acids Research</i> , 2014, 42, 7591-7610.	14.5	43
27	Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. <i>Molecular Cell</i> , 2021, 81, 4059-4075.e11.	9.7	42
28	Malignant adenomyoepithelioma of the breast metastasizing to the liver. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 442, 504-506.	2.8	40
29	PRDM1/BLIMP-1 Modulates IFN- $\gamma$ -Dependent Control of the MHC Class I Antigen-Processing and Peptide-Loading Pathway. <i>Journal of Immunology</i> , 2007, 179, 7614-7623.	0.8	40
30	Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. <i>Journal of Immunology</i> , 2017, 198, 4618-4628.	0.8	40
31	FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma. <i>Blood</i> , 2014, 124, 3118-3129.	1.4	35
32	Eosinophilic Bowel Disease Controlled by the BB Rat-Derived Lymphopenia/Gimap5 Gene. <i>Gastroenterology</i> , 2006, 131, 1475-1485.	1.3	34
33	Repression of IFN- $\gamma$ Induction of Class II Transactivator: A Role for PRDM1/Blimp-1 in Regulation of Cytokine Signaling. <i>Journal of Immunology</i> , 2006, 177, 4584-4593.	0.8	28
34	A Replicative Self-Renewal Model for Long-Lived Plasma Cells: Questioning Irreversible Cell Cycle Exit. <i>Frontiers in Immunology</i> , 2013, 4, 460.	4.8	28
35	Application of the LymphGen classification tool to 928 clinically and genetically characterized cases of diffuse large B cell lymphoma (DLBCL). <i>British Journal of Haematology</i> , 2021, 192, 216-220.	2.5	28
36	Expression pattern of XBP1(S) in human B-cell lymphomas. <i>Haematologica</i> , 2009, 94, 419-422.	3.5	27

#	ARTICLE	IF	CITATIONS
37	Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma. <i>Leukemia</i> , 2019, 33, 2884-2897.	7.2	26
38	S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells. <i>Leukemia</i> , 2018, 32, 214-223.	7.2	25
39	Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. <i>Molecular Cancer</i> , 2015, 14, 205.	19.2	24
40	Gene expression meta-analysis reveals immune response convergence on the IFN $\gamma$ -STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma. <i>Genome Medicine</i> , 2015, 7, 96.	8.2	24
41	Site-1 protease function is essential for the generation of antibody secreting cells and reprogramming for secretory activity. <i>Scientific Reports</i> , 2018, 8, 14338.	3.3	24
42	Amino Acid Deprivation Links BLIMP-1 to the Immunomodulatory Enzyme Indoleamine 2,3-Dioxygenase. <i>Journal of Immunology</i> , 2009, 183, 5768-5777.	0.8	22
43	Parsimonious Gene Correlation Network Analysis (PGCNA): a tool to define modular gene co-expression for refined molecular stratification in cancer. <i>Npj Systems Biology and Applications</i> , 2019, 5, 13.	3.0	22
44	TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism. <i>Cancer Research</i> , 2016, 76, 6975-6987.	0.9	21
45	Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas. <i>Genome Medicine</i> , 2015, 7, 64.	8.2	20
46	MHC Class-II Expression Reveals Differential Regulation of BLIMP-1 Target Genes.. <i>Blood</i> , 2005, 106, 1207-1207.	1.4	20
47	Cell-of-Origin in diffuse large B-cell lymphoma: findings from the UK's population-based Haematological Malignancy Research Network. <i>British Journal of Haematology</i> , 2019, 185, 781-784.	2.5	19
48	B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 769-779.	5.6	16
49	Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth. <i>Hepatology</i> , 2021, 74, 2561-2579.	7.3	13
50	Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network. <i>Blood Advances</i> , 2022, 6, 5716-5731.	5.2	12
51	Growth Factor-like Gene Regulation Is Separable from Survival and Maturation in Antibody-Secreting Cells. <i>Journal of Immunology</i> , 2019, 202, 1287-1300.	0.8	11
52	Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis. <i>Laboratory Investigation</i> , 2011, 91, 1298-1303.	3.7	8
53	Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma. <i>Journal of Pathology</i> , 2019, 248, 142-154.	4.5	8
54	Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance. <i>British Journal of Haematology</i> , 2021, 192, 599-604.	2.5	7

#	ARTICLE	IF	CITATIONS
55	TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation. <i>Blood Advances</i> , 2020, 4, 2821-2836.	5.2	5
56	Identification of Critical Transcriptomic Signaling Pathways in Patients with H Syndrome and Rosai-Dorfman Disease. <i>Journal of Clinical Immunology</i> , 2021, 41, 441-457.	3.8	4
57	Novel Case of Tripeptidyl Peptidase 2 Deficiency Associated with Mild Clinical Phenotype. <i>Journal of Clinical Immunology</i> , 2021, 41, 1123-1127.	3.8	4
58	A dichotomy of gene regulatory associations during the activated B-cell to plasmablast transition. <i>Life Science Alliance</i> , 2020, 3, e202000654.	2.8	4
59	Sequential Inverse Dysregulation of the RNA Helicases DDX3X and DDX3Y Facilitates MYC-Driven Lymphomagenesis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
60	An unusual late relapse. <i>International Journal of Laboratory Hematology</i> , 2001, 23, 197-199.	0.2	1
61	Highly selective <sc>SYK</sc> inhibitor, <sc>GSK</sc> 143, abrogates survival signals in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 927-930.	2.5	1
62	A System for In Vitro Generation of Mature Murine Plasma Cells Uncovers Differential <i>Blimp-1</i>/<i>Prdm1</i> Promoter Usage. <i>Journal of Immunology</i> , 2022, 208, 514-525.	0.8	1
63	THU0013â€¦Normal CD19-Negative Plasma Cells Are Biologically Distinct from Other Normal Plasma Cells and Likely To Be Involved in Lack of Response To B-Cell Depletion for Autoimmune Disorders. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 182.1-182.	0.9	0
64	THU0002â€¦Prevalence of Monoclonal B-Cell Disorders in Patients with Autoimmunity in The UK. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 178.2-178.	0.9	0
65	A category-free approach to prognostic modelling in aggressive non-Hodgkin B cell lymphomas based on large patient databases. <i>Hematological Oncology</i> , 2017, 35, 326-327.	1.7	0
66	THU0293â€¦B-cell responses to type I interferon define disease activity in SLE and can be measured by cell surface tetherin (CD317)., 2017, , .		0
67	Case-based discussion: a case of misdiagnosis of primary lung malignancy. <i>Thorax</i> , 2019, 74, 1003-1005.	5.6	0
68	BLIMP-1 Is a Target of Cellular Stress and Downstream of the Unfolded Protein Response.. <i>Blood</i> , 2005, 106, 2207-2207.	1.4	0
69	Feedback inhibition of indoleamine 2,3â€¦dioxygenase by BLIMPâ€¦1 in response to tryptophan depletion. <i>FASEB Journal</i> , 2008, 22, 1065.20.	0.5	0
70	An Expanded Set of Direct BLIMP-1 Targets Identifies Novel Links in Differentiation, Immune Response and Lymphoma.. <i>Blood</i> , 2009, 114, 1466-1466.	1.4	0
71	Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425). <i>Blood</i> , 2015, 126, 331-331.	1.4	0